Selectivity) study [abstract] . Blood 2008 ; 112 : Abstract 335 . 61 Hughes TP Branford S White DL . Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600 mg/day of imatinib as initial
Susan O'Brien, Ellin Berman, Hossein Borghaei, Daniel J. DeAngelo, Marcel P. Devetten, Steven Devine, Harry P. Erba, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Tariq Mughal, Javier Pinilla-Ibarz, Jerald P. Radich, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Martin S. Tallman, Moshe Talpaz and Meir Wetzler
Michael D. Stubblefield, Harold J. Burstein, Allen W. Burton, Christian M. Custodio, Gary E. Deng, Maria Ho, Larry Junck, G. Stephen Morris, Judith A. Paice, Sudhakar Tummala and Jamie H. Von Roenn
multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer . J Clin Oncol 2000 ; 18 : 136 – 147 . 19 Maindrault-Goebel F de Gramont A Louvet C . High-dose
Ludmila Katherine Martin and Tanios Bekaii-Saab
in long-term clinical outcomes (such as disease-free and overall survivals) with prolonged follow-up from phase III trials, its integration into standard neoadjuvant CRT should then be considered. However, maintaining dose intensity may prove
Louis Burt Nabors, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Paul Brown, Nicholas Butowski, Marc C. Chamberlain, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Jona Hattangadi-Gluth, Matthias Holdhoff, Larry Junck, Thomas Kaley, Ronald Lawson, Jay S. Loeffler, Mary P. Lovely, Paul L. Moots, Maciej M. Mrugala, Herbert B. Newton, Ian Parney, Jeffrey J. Raizer, Lawrence Recht, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills Jr, Lode J. Swinnen, David Tran, Nam Tran, Frank D. Vrionis, Stephanie Weiss, Patrick Yung Wen, Nicole McMillian and Anita M. Engh
high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma . Int J Radiat Oncol Biol Phys 2014 ; 88 : 793 - 800 . 61. Ney DE Carlson JA Damek DM . Phase II trial of
Paolo Marchetti, Raymond Voltz, Carmen Rubio, Didier Mayeur and Andreas Kopf
from supportive care or supportive therapies , which are prescribed to treat the side effects of disease-specific treatment or to allow for higher doses or dose intensities of the treatment to be delivered. A common understanding of the services
Boglarka Gyurkocza and Frederick R. Appelbaum
: the role of dose intensity . Leukemia 2006 ; 32 : 322 – 328 . 18. McClune B Weisdorf DJ DiPersio JF . Non-myeloablative hematopoietic stem cell transplantation in older patients with AML and MDS: results from the Center for International Blood and
Bhumsuk Keam, Jeong-Hoon Lee, Seock-Ah Im and Jung-Hwan Yoon
prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin’s lymphoma who receive cytotoxic chemotherapy . J Korean Med Sci 2003 ; 18 : 849 – 854 . 114 Leaw
Adrienne G. Waks and Ann H. Partridge
(intravenous vs oral), schedules, and durations, and although it is clear that greater cumulative dose confers an increased risk of CRA, the impact of administration route and dose intensity/duration on CRA is not known. 14 Although some data suggest that
Peter F. Coccia, Alberto S. Pappo, Jessica Altman, Smita Bhatia, Scott C. Borinstein, Joseph Flynn, A. Lindsay Frazier, Suzanne George, Robert Goldsby, Robert Hayashi, Mary S. Huang, Rebecca H. Johnson, Lynda Kwon Beaupin, Michael P. Link, Kevin C. Oeffinger, Kathleen M. Orr, Damon Reed, Holly L. Spraker, Deborah A. Thomas, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Brad Zebrack, Dorothy A. Shead and Hema Sundar
major consequence of cancer and its treatment in both men and women. 6 , 7 The impact of cancer treatment on fertility is related to patient age at the time of diagnosis and the treatment, and is dependent on the type, duration, and dose intensity of
Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III and Tanya Wildes
representative of the general older population, because they were probably healthier than most older patients. Many of the treatment regimens used in these trials had lower dose-intensity than those in current use. Nevertheless, these studies are important
